Glioblastoma multiforme (GBM) is a particularly aggressive and devastating type of brain cancer. It progresses rapidly, often resists standard treatments, and comes with a median survival time of just over a year. Even with advances in surgery, radiation, and chemotherapy, the prognosis remains grim for most patients. This is largely because GBM tumors are highly invasive and adept at evading the immune system, making them exceptionally difficult to treat.
-copy-29e15046.jpeg?w=600)
